A STUDY TO EVALUATE THE EFFICACY OF ALFUZOSIN IN ACUTE URINARY RETENTION

Dr Samir Anand, Dr Naveed Anjum Qureshi, Dr Money Gupta

Abstract


There has been an increasing trend towards the use of drugs in both the progression and treatment of AUR due to prostatic obstruction. The immediate management of AUR requires bladder decompression by catheterisation. Until recently, secondary management consisted exclusively of BPH surgery performed either within a few days after AUR (emergency surgery) or within 1 to 3 months after the event, with the patient returning home with a catheter in situ during the interval. AIMS AND OBJECTIVE: 1. To study the efficacy of alfuzosin in acute urinary retention. 2. To observe its side effects. MATERIALAMD METHODS: Group I (Control): 50 patients were taken under consideration and advised analgesics/antibiotics as and when required during trial period. Group II (Study): 50 patients were given Tab. Alfuzosin 10mg in morning and analgesic/antibiotics as and when required during trial period. These patients were catheterized and catheter was removed after 3 days.

Full Text:

PDF

References


Emberton M, Andriol GL, De La Rosette J et al.: Benign prostatic hyperplasia: a

progressive disease of aging men. Urology 61, 267–273 (2003).

Emberton M: The hallmarks of benign prostatic hyperplasia progression and risk

factors. Eur. Urol. (Suppl. 2), 2–7 (2003).

Crawford ED, Wilson SS, Mcconnell JD et al (MTOPS research group): Baseline factors

as predictors of clinical progression of benign prostatic hyperplasia in men treated with

placebo

Roberts RO, Lieber MM, Jacobson DJ, Girman CJ, Jacobsen SJ: Limitation of using

outcomes in the placebo arm of a clinical trial of benign prostatic hyperplasia to

quantify those in the community. Mayo Clinic Proc. 80, 759–764 (2005).

Fitzpatrick JM: The natural history of benign prostatic hyperplasia. BJU Int.97(Suppl.

, 3–6 (2006).

Hartung R: Do α blockers prevent the occurrence of acute urinary retention? Eur. Urol.

(Suppl. 6), 13–18 (2001).

Thomas K, Oades G, Taylor-Hay C, Kirby RS: Acute urinary retention: what is the

impact on patient quality of life? BJU Int. 95, 72–76 (2005).

McConnell JD: Benign prostatic hyperplasia: Diagnosis and treatment in clinical

practice guidelines. AHCPR Publications, MD, USA, 8, 94–582 (1994).

Holtgrewe HL, Mebust WK, Dawd JB, Cockett AT, Peters PC, Proctor C: Transurethral

prostatectomy: practice aspect of the dominant operation in American urology. Urology

, 248–253 (1989).

Emberton M, Neal DE, Black N: The National prostatectomy audit: The clinical

management of patients during hospital admission. BJU 75, 301–316 (1995).

Pickard R, Emberton M, Neal DE: The management of men with acute urinary retention.

BJU 81, 712–720 (1998).

Taube M, Gajraj H: Trial without catheter following acute urinary retention. BJU 63,

–182 (1989).

Murray K, Massey A, Feneley RC: Acute urinary retention – an uro dynamic assessment.

BJU 56, 468–473 (1984).

Klarsove P, Andersen JT, Asmussen CF, Brenoe J, Jensen SK, Jensen IL: Symptoms and

signs predictive of the voiding patterns after acute urinary retention in men. Scand. J.

Urol. Nephrol. 21, 32–28 (1987).

McNeill SA: Does acute urinary retention respond to α blockers alone? Eur.

Urol.39(Suppl. 6), 7–12 (2001).

McNeill SA: The role of α-blockers in the management of acute urinary retention caused

by benign prostatic obstruction. Eur.


Refbacks

  • There are currently no refbacks.